Crosspoint Capital Strategies’s Edwards Lifesciences EW Stock Holding History

Crosspoint Capital Strategies’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-96,411	Closed	-$3.87M	–	136
2016 Q3	$3.87M	Sell	96,411 -1,872	-2%	-$70.5K	5.24%	10
2016 Q2	$3.27M	Buy	+98,283	New	+$3.36M	3.35%	21
2016 Q1	–	Sell	-315	Closed	-$13K	–	323
2015 Q4	$13K	Buy	315 +99	+46%	+$2.57K	﹤0.01%	665
2015 Q3	$5K	Sell	216 -7,668	-97%	-$185K	0.01%	499
2015 Q2	$187K	Sell	7,884 -139,302	-95%	-$3.14M	0.05%	202
2015 Q1	$3.5M	Sell	147,186 -1,920	-1%	-$43.1K	1.69%	16
2014 Q4	$3.17M	Buy	+149,106	New	+$3M	1.1%	32

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Crosspoint Capital Strategies's EW Position: Q4 2016 in Review

Crosspoint Capital Strategies sold out of Edwards Lifesciences (EW) in Q4 2016, closing a stake of 96,411 shares — an estimated $3.87M sold.

Crosspoint Capital Strategies first reported a position in EW in Q4 2014 and held it in 7 quarters. The position peaked at $3.87M in Q3 2016. 686 funds tracked by Wall St. Rank hold EW as of Q4 2016.

Crosspoint Capital Strategies reported no remaining Edwards Lifesciences position as of Q4 2016 after selling out during the quarter.
Crosspoint Capital Strategies sold 96,411 Edwards Lifesciences shares in Q4 2016, an estimated $3.87M.
Crosspoint Capital Strategies first reported a position in Edwards Lifesciences in Q4 2014 and held it in 7 quarters.
Crosspoint Capital Strategies's Edwards Lifesciences position peaked at $3.87M in Q3 2016.
686 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q4 2016, filed 23 Jan 2017.